Recent Advances in Surgical Strategies for Managing Metastatic Colorectal Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: 15 December 2025 | Viewed by 392
Special Issue Editors
Interests: HPB surgery; peritoneal surface malignancy; liver mets; CRS +/− HIPEC; laparoscopic surgery; colorectal cancer
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) is the second most lethal form of cancer worldwide, and the prognosis for metastatic CRC (mCRC) remains poor. Over the last two decades, different treatment modalities for mCRC have emerged. The introduction of molecular targeting has significantly improved patient outcomes. The availability of new chemoimmunotherapeutic protocols coupled with the possibility of integrating different surgical procedures has made it possible in recent years to create new therapeutic strategies for the treatment of metastatic disease in selected patients, especially with regard to liver and/or peritoneal surface metastases (PSMs). The treatment of metastases at other sites (lung, brain, adrenals, etc.) has also benefited from the progress achieved.
This Special Issue will collect research on the latest advances in tools and strategies to treat mCRC.
In the treatment of liver metastases, the main innovations are related to the following:
- “Parenchymal sparing” liver surgery using either a traditional or minimally invasive technique, whether associated or not associated with resection of the primary tumor;
- Advanced “parenchymal sparing” surgery: horseshoe hepatectomy, right upper transverse hepatectomy, etc.;
- The introduction of the “liver-first” approach;
- The improvement of techniques (surgical and radiological) used to increase the “future liver remnant”;
- “R1 vascular liver resection”;
- The intraoperative use of ICG to identify lesions and assess parenchyma perfusion;
- The possibility of using of liver volume 3D simulation software or an AI model to define the best “tailored” therapeutic strategies;
- The chance to use selective transarterial radioembolisation for unresectable liver cancer.
With regard to PSM, since the publication of the Prodige 7 study, cytoreductive surgery (CRS) has been recognized as a therapeutic “corner-stone”; however, the debate is still heated with regard to the below issues:
- The actual usefulness of HIPEC;
- The best HIPEC protocol;
- The roles of EPIC and PIPAC procedures;
- The best timing for chemotherapy (neoadjuvant, adjuvant, both);
- The feasibility of a minimally invasive approach
We welcome original articles on basic, pre-clinical, clinical, and translational research, as well as systematic reviews adhering to the above-described theme.
Dr. Fabrizio D'Acapito
Dr. Marco Vaira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic colorectal cancer
- liver metastases
- parenchymal-sparing hepatectomy
- staged hepatectomy
- minimally invasive liver resection
- cytoreductive surgery
- HIPEC
- PIPAC
- peritoneal surface metastases
- biomarker-based stratification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
